You just read:

Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

News provided by

Cardiff Oncology, Inc.

May 13, 2020, 08:15 ET